News|Articles|October 21, 2026

Supplements And Featured Publications

  • Long-Term Repigmentation Outcomes With OPZELURA® (Ruxolitinib) Cream 1.5% in Nonsegmental Vitiligo Regardless of Baseline Disease Activity

Long-Term Repigmentation Outcomes With OPZELURA® (Ruxolitinib) Cream 1.5% in Nonsegmental Vitiligo Regardless of Baseline Disease Activity

Sponsored by Incyte.


Related to this article

Eric K. Singhi, M.D., on lung cancer among younger adults
Young-onset lung cancer often strikes nonsmokers, and current screening based on smoking is not likely to find it, says Singhi, an assistant professor at UT MD Anderson Cancer Center in Houston. New risk-based screening, liquid biopsies, and breath tests aim earlier detection.